Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial ribosomal protein L42 (MRPL42) is a structural protein encoded by a nuclear gene, essential for the assembly and function of the mitochondrial ribosome (mitoribosome) in human cells. It participates in mitochondrial protein synthesis by forming part of both the small (28S) and large (39S) ribosomal subunits, although definitive subunit assignment remains under study. Unlike prokaryotic ribosomal proteins, mammalian mitoribosomal proteins, including MRPL42, have diverged significantly in sequence, complicating cross-species identification by homology. There are multiple transcript variants and pseudogenes of MRPL42 identified in the human genome. MRPL42's core function is as a structural constituent of the ribosome, facilitating mitochondrial translation that is essential for cellular energy metabolism. Mutation or dysfunction can disturb mitochondrial biogenesis, but MRPL42 itself has not been characterized as a direct therapeutic target and no drugs or specific inhibitors are currently known that act on MRPL42.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial ribosomal protein L42 (MRPL42).